Table 1.

Baseline Patient Demographics and Disease Characteristics

	Pazopanib (n = 557)	Sunitinib (n = 553)
Median age, years (range)	61 (18-88)	62 (23–86)
Male sex, n (%)	398 (71)	415 (75)
Prior nephrectomy, n (%)	459 (82)	465 (84)
Karnofsky performance status, n (%)
70 or 80	141 (25)	130 (24)
90 or 100	416 (75)	423 (76)
Lactate dehydrogenase, n (%)
> 1.5 × ULN	40 (7)	29 (5)
≤ 1.5 × ULN	517 (93)	524 (95)
Most common metastatic sites, n (%)
Lung	424 (76)	425 (77)
Lymph node	223 (40)	247 (45)
Bone	110 (20)	85 (15)
Liver	86 (15)	110 (20)
MSKCC risk category,* n (%)
Favorable	151 (27)	152 (27)
Intermediate	322 (58)	328 (59)
Poor	67 (12)	52 (9)
Unknown	17 (3)	21 (4)

Abbreviations: MSKCC, Memorial Sloan-Kettering Cancer Center; ULN, upper limit of normal.

^*Revicki DA, et al.⁶